TOP > 外国特許検索 > IgG binding peptide

IgG binding peptide

外国特許コード F130007492
掲載日 2013年7月10日
出願国 アメリカ合衆国
出願番号 31226807
公報番号 20100297606
公報番号 8372950
出願日 平成19年11月2日(2007.11.2)
公報発行日 平成22年11月25日(2010.11.25)
公報発行日 平成25年2月12日(2013.2.12)
国際出願番号 JP2007071754
国際公開番号 WO2008054030
国際出願日 平成19年11月2日(2007.11.2)
国際公開日 平成20年5月8日(2008.5.8)
優先権データ
  • 特願2006-299566 (2006.11.2) JP
  • 2007WO-JP71754 (2007.11.2) WO
発明の名称 (英語) IgG binding peptide
発明の概要(英語) (US8372950)
The present invention provides a peptide capable of specifically binding to human IgG.
In particular, the present invention relates to a human IgG binding peptide tag of 11 to 16 amino acids in length, comprising at least an amino acid sequence of the formula I: C-(X)n-W-X-X-X-W-(X)m-C (I) (SEQ ID NO: 17) wherein n and m are each an integer of 1 or more and the sum n+m is 4 or 5, wherein X-X-X in the formula I contains no cysteine residue, and wherein said amino acid sequence satisfies either or both of a) and b): a) (X)n-W in the formula I denotes Za-G-Y-W (SEQ ID NO: 18); and b) W-(X)m in the formula I denotes W-G-L-Zb (SEQ ID NO: 19) wherein Za and Zb are each 0, 1, or more amino acid residues.
特許請求の範囲(英語) [claim1]
1. A human IgG binding peptide tag that is 11 to 16 amino acids in length, comprising at least an amino acid sequence of formula I:
C-(X)n-W-X-X-X-W-(X)m-C (I) (SEQ ID NO: 17)
wherein n and m are each an integer of 1 or more and the sum n+m is 4 or 5, wherein X-X-X in the formula I contains no cysteine residue, and
wherein said amino acid sequence satisfies either or both of a) and b): a) (X)n-W in the formula I is Za-G-Y-W (SEQ ID NO: 18); and
b) W-(X)m in the formula I is W-G-L-Zb (SEQ ID NO: 19)
wherein Za and Zb are each 0, 1, or more amino acid residues.
[claim2]
2. The peptide tag according to claim 1, wherein said amino acid sequence of the formula I satisfies both a) and b): a) (X)n-W in the formula I is Za-G-Y-W (SEQ ID NO: 18); and
b) W-(X)m in the formula I is W-G-L-Zb (SEQ ID NO: 19)
wherein Za and Zb are each 0, 1, or more amino acid residues.
[claim3]
3. The peptide tag according to claim 1, which consists of any of the amino acid sequences 1) to 11):
1) CGYWRSEWGLC;(SEQ ID NO: 1) 2) CTGFWEREWGLC;(SEQ ID NO: 2) 3) CLYWPRLWGLC;(SEQ ID NO: 3) 4) CTGYWPKAWGLC;(SEQ ID NO: 4) 5) CYWAVRWGLLGC;(SEQ ID NO: 5) 6) CGYWADVWQIHC;(SEQ ID NO: 6) 7) GCGYWRSEWGLCG;(SEQ ID NO: 7) 8) GCTGFWEREWGLCG;(SEQ ID NO: 8) 9) GCTGYWPKAWGLCG;(SEQ ID NO: 9)10) GCGYWRSQWGLCG;(SEQ ID NO: 10)and11) GCTGYWPRAWGLCG(SEQ ID NO: 11).
[claim4]
3. The peptide tag according to
-- 1) CGYWRSEWGLC; (SEQ ID NO: 1)
--
-- 2) CTGFWEREWGLC; (SEQ ID NO: 2)
--
-- 3) CLYWPRLWGLC; (SEQ ID NO: 3)
--
-- 4) CTGYWPKAWGLC; (SEQ ID NO: 4)
--
-- 5) CYWAVRWGLLGC; (SEQ ID NO: 5)
--
-- 6) CGYWADVWQIHC; (SEQ ID NO: 6)
--
-- 7) GCGYWRSEWGLCG; (SEQ ID NO: 7)
--
-- 8) GCTGFWEREWGLCG; (SEQ ID NO: 8)
--
-- 9) GCTGYWPKAWGLCG; (SEQ ID NO: 9)
--
-- 10) GCGYWRSQWGLCG; (SEQ ID NO: 10)
-- and
--
-- 11) GCTGYWPRAWGLCG (SEQ ID NO: 11).
[claim5]
4. The peptide tag according to any claim 1, wherein a disulfide bond is formed between two cysteine residues in formula I.
[claim6]
5. The peptide tag according to claim 1, which binds to acid-denatured human IgG.
[claim7]
6. A human IgG binding peptide tag that is 11 to 16 amino acids in length, comprising at least an amino acid sequence of formula I:
-- C-(X)n-W-X-X-X-W-(X)m-C (I) (SEQ ID NO: 17)
[claim8]
7. A fusion protein of the following formula: P1-C-(X)n-W-X-X-X-W-(X)m-C-P2
wherein
C-(X)n-W-X-X-X-W-(X)m-C(I)(SEQ ID NO: 17)
is a human IgG binding peptide tag that is 11 to 16 amino acids in length,
wherein n and m are each an integer of 1 or more and the sum n+m is 4 or 5, wherein X-X-X in the formula contains no cysteine residue, and
wherein said human IgG binding peptide tag satisfies either or both of a) and b): a) (X)n-W in the formula is Za-G-Y-W (SEQ ID NO: 18); and
b) W-(X)m in the formula is W-G-L-Zb (SEQ ID NO: 19)
wherein Za and Zb are each 0, 1, or more amino acid residues,
wherein either of P1 and P2 is present, but P1 and P2 are not both present at the same time,
wherein P1, when present, is bonded to the N-terminus of the human IgG binding peptide tag C-(X)n-W-X-X-X-W-(X)m-C (SEQ ID NO:17),
wherein P2, when present, is bonded to the C-terminus of the human IgG binding peptide tag C-(X)n-W-X-X-X-W-(X)m-C (SEQ ID NO:17),
and wherein P1 and P2 each represents a protein.
[claim9]
7. A fusion protein of the following formula:
-- C-(X)n-W-X-X-X-W-(X)m-C (I) (SEQ ID NO: 17)
[claim10]
8. A solid phase support, on which the peptide tag according to claim 1 is immobilized.
[claim11]
9. A method for determining the presence of human IgG or an Fc region-containing fragment thereof in a sample, comprising the steps a) to c): a) contacting a sample with acid to produce an acid-treated sample;
b) contacting the acid-treated sample with the peptide tag according to claim 1; and
c) measuring a binding affinity produced in the step b) between the peptide tag and human IgG or an Fc region-containing fragment thereof, wherein the binding affinity having a dissociation constant of 0.1 nM to 50 nM indicates the presence of human IgG or an Fc region-containing fragment thereof in a sample.
[claim12]
10. The method according to claim 9, wherein the binding affinity is measured by surface plasmon resonance analysis.
[claim13]
11. A method for purifying human IgG or an Fc region-containing fragment thereof in a sample, comprising the steps a) and b): a) contacting the peptide tag according to claim 1 with an acid-treated sample containing human IgG or an Fc region-containing fragment thereof, thereby binding human IgG or an Fc region-containing fragment thereof in the sample to the peptide tag; and
b) separating the human IgG or the Fc region-containing fragment thereof, which is bound to the peptide tag in the step a), from the sample.
[claim14]
12. A method for removing an acid-denatured human IgG or Fc region-containing fragment thereof from a sample, comprising the steps a) and b): a) contacting the peptide tag according to claim 1 with a sample containing acid-denatured human IgG or an Fc region-containing fragment thereof; and
b) removing human IgG or an Fc region-containing fragment thereof bound to the peptide tag prepared by the step a), from the sample.
[claim15]
13. A method for purifying a protein, comprising the steps a) to c): a) producing a fusion protein according to claim 7, and then preparing a sample containing the fusion protein;
b) contacting the sample prepared by step a) with acid-treated human IgG or an Fc region-containing fragment thereof, thereby binding the fusion protein to the human IgG or Fc region-containing fragment thereof; and
c) separating the fusion protein, which is bound to the human IgG or Fc region-containing fragment thereof in the step b), from the sample.
  • 発明者/出願人(英語)
  • ITO YUJI
  • KAGOSHIMA UNIVERSITY
国際特許分類(IPC)
米国特許分類/主・副
  • C07K001/22
  • C07K007/06
  • C07K007/08
  • G01N033/68B2
  • G01N033/68B
特許の内容に興味を持たれた方、ライセンスをご希望の方は、下記「問合せ先」までお問い合わせください。

PAGE TOP

close
close
close
close
close
close